BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR. Epidemiology of Poliomyelitis in the United States One Decade after the Last Reported Case of Indigenous Wild Virus-Associated Disease. Clinical Infectious Diseases 1992;14:568-79. [DOI: 10.1093/clinids/14.2.568] [Cited by in Crossref: 205] [Cited by in F6Publishing: 139] [Article Influence: 7.1] [Reference Citation Analysis]
Number Citing Articles
1 Grassly NC. The final stages of the global eradication of poliomyelitis. Philos Trans R Soc Lond B Biol Sci 2013;368:20120140. [PMID: 23798688 DOI: 10.1098/rstb.2012.0140] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
2 Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, Persu A, Aubert-Combiescu A, Delpeyroux F, Crainic R. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J Virol 2000;74:8434-43. [PMID: 10954543 DOI: 10.1128/jvi.74.18.8434-8443.2000] [Cited by in Crossref: 154] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
3 Yang CF, Chen HY, Jorba J, Sun HC, Yang SJ, Lee HC, Huang YC, Lin TY, Chen PJ, Shimizu H, Nishimura Y, Utama A, Pallansch M, Miyamura T, Kew O, Yang JY. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol 2005;79:12623-34. [PMID: 16188964 DOI: 10.1128/JVI.79.20.12623-12634.2005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
4 Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996;14:735-46. [DOI: 10.1016/0264-410x(95)00211-i] [Cited by in Crossref: 79] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
5 Martín J, Crossland G, Wood DJ, Minor PD. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. Journal of General Virology 2003;84:1781-8. [DOI: 10.1099/vir.0.19088-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
6 Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172:1213-29. [PMID: 20978089 DOI: 10.1093/aje/kwq320] [Cited by in Crossref: 243] [Cited by in F6Publishing: 162] [Article Influence: 22.1] [Reference Citation Analysis]
7 Burns CC, Campagnoli R, Shaw J, Vincent A, Jorba J, Kew O. Genetic inactivation of poliovirus infectivity by increasing the frequencies of CpG and UpA dinucleotides within and across synonymous capsid region codons. J Virol 2009;83:9957-69. [PMID: 19605476 DOI: 10.1128/JVI.00508-09] [Cited by in Crossref: 120] [Cited by in F6Publishing: 78] [Article Influence: 10.0] [Reference Citation Analysis]
8 Sutter RW, Prevots DR, Cochi SL. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr Clin North Am 2000;47:287-308. [PMID: 10761505 DOI: 10.1016/s0031-3955(05)70208-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine: . The Pediatric Infectious Disease Journal 1997;16:312-22. [DOI: 10.1097/00006454-199703000-00011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
10 Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, Pate MA, Abanida EA, Gasasira A, Iber J, Chen Q, Vincent A, Chenoweth P, Henderson E, Wannemuehler K, Naeem A, Umami RN, Nishimura Y, Shimizu H, Baba M, Adeniji A, Williams AJ, Kilpatrick DR, Oberste MS, Wassilak SG, Tomori O, Pallansch MA, Kew O. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013;87:4907-22. [PMID: 23408630 DOI: 10.1128/JVI.02954-12] [Cited by in Crossref: 108] [Cited by in F6Publishing: 55] [Article Influence: 13.5] [Reference Citation Analysis]
11 Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. "Endgame" issues for the global polio eradication initiative. Clin Infect Dis 2002;34:72-7. [PMID: 11731948 DOI: 10.1086/338262] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
12 Miller ER, Moro PL, Cano M, Shimabukuro TT. Deaths following vaccination: What does the evidence show? Vaccine 2015;33:3288-92. [PMID: 26004568 DOI: 10.1016/j.vaccine.2015.05.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
13 O'Hagan DT, Rappuoli R. The safety of vaccines. Drug Discov Today 2004;9:846-54. [PMID: 15381137 DOI: 10.1016/S1359-6446(04)03234-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
14 Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 2008;3:e3433. [PMID: 18958288 DOI: 10.1371/journal.pone.0003433] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
15 Tuttle J, Chen RT, Rantala H, Cherry JD, Rhodes PH, Hadler S. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health 1997;87:2045-8. [PMID: 9431302 DOI: 10.2105/ajph.87.12.2045] [Cited by in Crossref: 55] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
16 Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus Vaccine–Live. Plotkin's Vaccines. Elsevier; 2018. pp. 866-917.e16. [DOI: 10.1016/b978-0-323-35761-6.00048-1] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Weibel RE, Benor DE. Reporting vaccine-associated paralytic poliomyelitis: concordance between the CDC and the National Vaccine Injury Compensation Program. Am J Public Health 1996;86:734-7. [PMID: 8629730 DOI: 10.2105/ajph.86.5.734] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
18 Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination. Ann NY Acad Sci 1995;754:289-99. [DOI: 10.1111/j.1749-6632.1995.tb44462.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 1.6] [Reference Citation Analysis]
19 Wadsworth L. Polio immunization: Dealing with new recommendations and helping parents understand the changes. Journal of Pediatric Health Care 1999;13:S21-6. [DOI: 10.1016/s0891-5245(99)90065-2] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 de Melo AB, da Silva Mda P, Magalhães MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 2011;85:739-47. [PMID: 21976581 DOI: 10.4269/ajtmh.2011.10-0496] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
21 Combiescu M, Guillot S, Persu A, Baicus A, Pitigoi D, Balanant J, Oprisan G, Crainic R, Delpeyroux F, Aubert-combiescu A. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch Virol 2007;152:727-38. [DOI: 10.1007/s00705-006-0884-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
22 Pliaka V, Kyriakopoulou Z, Tsakogiannis D, Ruether IGA, Gartzonika C, Levidiotou-stefanou S, Krikelis A, Markoulatos P. Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains. Eur J Clin Microbiol Infect Dis 2010;29:1513-23. [DOI: 10.1007/s10096-010-1033-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Kindberg E, Ax C, Fiore L, Svensson L. Ala67Thr mutation in the poliovirus receptor CD155 is a potential risk factor for vaccine and wild-type paralytic poliomyelitis. J Med Virol 2009;81:933-6. [PMID: 19319949 DOI: 10.1002/jmv.21444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Dedepsidis E, Pliaka V, Kyriakopoulou Z, Brakoulias C, Levidiotou-Stefanou S, Pratti A, Mamuris Z, Markoulatos P. Complete genomic characterization of an intertypic Sabin 3/Sabin 2 capsid recombinant. FEMS Immunol Med Microbiol 2008;52:343-51. [PMID: 18328076 DOI: 10.1111/j.1574-695X.2008.00381.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
25 Genito CJ, Batty CJ, Bachelder EM, Ainslie KM. Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. Adv Nanobiomed Res 2021;:2000041. [PMID: 33681864 DOI: 10.1002/anbr.202000041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
26 Rakoto-Andrianarivelo M, Guillot S, Iber J, Balanant J, Blondel B, Riquet F, Martin J, Kew O, Randriamanalina B, Razafinimpiasa L, Rousset D, Delpeyroux F. Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar. PLoS Pathog 2007;3:e191. [PMID: 18085822 DOI: 10.1371/journal.ppat.0030191] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
27 Paximadi E, Karakasiliotis I, Bolanaki E, Krikelis A, Markoulatos P. Vaccine derived bi- and multi-recombinant Sabin strains. Virus Genes 2007;35:541-8. [PMID: 17680217 DOI: 10.1007/s11262-007-0146-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
28 Martín J, Ferguson GL, Wood DJ, Minor PD. The Vaccine Origin of the 1968 Epidemic of Type 3 Poliomyelitis in Poland. Virology 2000;278:42-9. [DOI: 10.1006/viro.2000.0614] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
29 Shulman LM. Polio and Its Epidemiology. In: Kanki P, Grimes DJ, editors. Infectious Diseases. New York: Springer; 2013. pp. 237-308. [DOI: 10.1007/978-1-4614-5719-0_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Kim SJ, Kim SH, Jee YM, Kim JS. Vaccine-associated paralytic poliomyelitis: a case report of flaccid monoparesis after oral polio vaccine. J Korean Med Sci 2007;22:362-4. [PMID: 17449951 DOI: 10.3346/jkms.2007.22.2.362] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Martín J, Minor PD. Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 2002;76:5339-49. [PMID: 11991962 DOI: 10.1128/jvi.76.11.5339-5349.2002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
32 Karakasiliotis I, Markoulatos P, Katsorchis T. Site analysis of recombinant and mutant poliovirus isolates of Sabin origin from patients and from vaccinees. Mol Cell Probes 2004;18:103-9. [PMID: 15051119 DOI: 10.1016/j.mcp.2003.09.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
33 Old MO, Martinez CV, Kwock D, Garcia J, Martin G, Chan C, Maldonado YA. Direct extraction of Sabin poliovirus genomes from human fecal samples using a guanidine thiocyanate extraction method. J Virol Methods 2003;110:193-200. [PMID: 12798248 DOI: 10.1016/s0166-0934(03)00133-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Laassri M, Dragunsky E, Enterline J, Eremeeva T, Ivanova O, Lottenbach K, Belshe R, Chumakov K. Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization. J Clin Microbiol 2005;43:2886-94. [PMID: 15956413 DOI: 10.1128/JCM.43.6.2886-2894.2005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
35 Fiore L, Novello F, Simeoni P, Amato C, Vellucci L, De Stefano D, Grandolfo ME, Luzzi I. Surveillance of acute flaccid paralysis in Italy: 1996-1997. AFP Study Group. Acute flaccid paralysis. Eur J Epidemiol 1999;15:757-63. [PMID: 10555620 DOI: 10.1023/a:1007697421114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
36 Paul Y. Oral polio vaccines and their role in polio eradication in India. Expert Rev Vaccines 2009;8:35-41. [PMID: 19093771 DOI: 10.1586/14760584.8.1.35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
37 Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. Vaccines. Elsevier; 2008. pp. 605-29. [DOI: 10.1016/b978-1-4160-3611-1.50029-5] [Cited by in Crossref: 15] [Article Influence: 1.2] [Reference Citation Analysis]
38 Esteves-Jaramillo A, Estívariz CF, Peñaranda S, Richardson VL, Reyna J, Coronel DL, Carrión V, Landaverde JM, Wassilak SG, Pérez-Sánchez EE, López-Martínez I, Burns CC, Pallansch MA. Detection of vaccine-derived polioviruses in Mexico using environmental surveillance. J Infect Dis 2014;210 Suppl 1:S315-23. [PMID: 25316850 DOI: 10.1093/infdis/jiu183] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
39 Tano Y, Shimizu H, Martin J, Nishimura Y, Simizu B, Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007;25:7041-6. [DOI: 10.1016/j.vaccine.2007.07.060] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
40 Wilson CB, Marcuse EK. Vaccine safety--vaccine benefits: science and the public's perception. Nat Rev Immunol 2001;1:160-5. [PMID: 11905824 DOI: 10.1038/35100585] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
41 Huang DB, Wu JJ, Tyring SK. A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines. J Infect 2004;49:179-209. [PMID: 15337336 DOI: 10.1016/j.jinf.2004.05.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
42 Drebot MA, Mulders MN, Campbell JJ, Kew OM, Fonseca K, Strong D, Lee SH. Molecular detection of an importation of type 3 wild poliovirus into Canada from The Netherlands in 1993. Appl Environ Microbiol 1997;63:519-23. [DOI: 10.1128/aem.63.2.519-523.1997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 McPhillips H, Marcuse EK. Vaccine safety. Curr Probl Pediatr 2001;31:91-121. [PMID: 11330034 DOI: 10.1016/s1538-5442(01)70025-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
44 Shahmahmoodi S, Parvaneh N, Burns C, Asghar H, Mamishi S, Tabatabaie H, Chen Q, Teimourian S, Gooya MM, Esteghamati A, Mousavi T, Yousefi M, Farrokhi K, Mashlool M, Kew O, Nategh R. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Research 2008;137:168-72. [DOI: 10.1016/j.virusres.2008.07.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
45 Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006;26:1423-40. [PMID: 17184390 DOI: 10.1111/j.1539-6924.2006.00831.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
46 Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 1998;4:229-37. [PMID: 9621193 DOI: 10.3201/eid0402.980210] [Cited by in Crossref: 132] [Cited by in F6Publishing: 99] [Article Influence: 5.7] [Reference Citation Analysis]
47 Pliaka V, Kyriakopoulou Z, Markoulatos P. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines 2012;11:609-28. [PMID: 22827246 DOI: 10.1586/erv.12.28] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
48 Mallet L, Pelloquin F, Brigaud M, Caudrelier P, Bandet R, Xueref C, Fuchs F, Gibelin N, Goldman C, Moulin JC, de Fraipont F, Montagnon B, Peyron L, Aymard M. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells. J Med Virol 1997;52:50-60. [DOI: 10.1002/(sici)1096-9071(199705)52:1<50::aid-jmv9>3.0.co;2-q] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
49 Beausoleil JL, Nordgren RE, Modlin JF. Vaccine-Associated Paralytic Poliomyelitis. J Child Neurol 1994;9:334-5. [DOI: 10.1177/088307389400900324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 3.2] [Reference Citation Analysis]
50 Karch CP, Burkhard P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol 2016;120:1-14. [PMID: 27157411 DOI: 10.1016/j.bcp.2016.05.001] [Cited by in Crossref: 105] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
51 Shulman LM, Manor Y, Handsher R, Delpeyroux F, Mcdonough MJ, Halmut T, Silberstein I, Alfandari J, Quay J, Fisher T, Robinov J, Kew OM, Crainic R, Mendelson E. Molecular and Antigenic Characterization of a Highly Evolved Derivative of the Type 2 Oral Poliovaccine Strain Isolated from Sewage in Israel. J Clin Microbiol 2000;38:3729-34. [DOI: 10.1128/jcm.38.10.3729-3734.2000] [Cited by in Crossref: 76] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
52 Halsey NA. The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis 2002;13:205-14. [PMID: 12199617 DOI: 10.1053/spid.2002.125864] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
53 Tebbens RJD, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM. Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication. Risk Analysis 2006;26:1471-505. [DOI: 10.1111/j.1539-6924.2006.00827.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 95] [Article Influence: 8.0] [Reference Citation Analysis]
54 Reed MD, de Clavijo IV, Weart CW. Update on Childhood Immunizations. Ann Pharmacother 1994;28:633-42. [DOI: 10.1177/106002809402800514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
55 Vidor E, Caudrelier P, Plotkin S. The place of DTP/eIPV vaccine in routine pediatric vaccination. Rev Med Virol 1994;4:261-77. [DOI: 10.1002/rmv.1980040405] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
56 D'souza RM, Watson C, Kennett M. Australia's contribution to global polio eradication initiatives. Australian and New Zealand Journal of Public Health 1999;23:289-94. [DOI: 10.1111/j.1467-842x.1999.tb01258.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Zangwill KM, Yeh SH, Wong EJ, Marcy SM, Eriksen E, Huff KR, Lee M, Lewis EM, Black SB, Ward JI. Paralytic Syndromes in Children: Epidemiology and Relationship to Vaccination. Pediatric Neurology 2010;42:206-12. [DOI: 10.1016/j.pediatrneurol.2009.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
58 Dutta A. Epidemiology of poliomyelitis—Options and update. Vaccine 2008;26:5767-73. [DOI: 10.1016/j.vaccine.2008.07.101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
59 Alexander J, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, Cebelinski E, Chen Q, Jorba J, Kew O, Pallansch M, Oberste M, Schleiss M, Davis J, Warshawsky B, Squires S, Hull H; Vaccine‐Derived Poliovirus Investigations Group. Transmission of Imported Vaccine‐Derived Poliovirus in an Undervaccinated Community in Minnesota. J INFECT DIS 2009;199:391-7. [DOI: 10.1086/596052] [Cited by in Crossref: 70] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
60 Rezapkin GV, Alexander W, Dragunsky E, Parker M, Pomeroy K, Asher DM, Chumakov KM. Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine. Virology 1998;245:183-7. [PMID: 9636357 DOI: 10.1006/viro.1998.9191] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
61 Cáceres V, Sutter R. Sabin Monovalent Oral Polio Vaccines: Review of Past Experiences and Their Potential Use after Polio Eradication. CLIN INFECT DIS 2001;33:531-41. [DOI: 10.1086/321905] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
62 Chitsike I, van Furth R. Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report. BMJ 1999;318:841-3. [PMID: 10092261 DOI: 10.1136/bmj.318.7187.841] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
63 Modlin JF. Poliomyelitis and Poliovirus Immunization. In: Rotbart HA, editor. Human Enterovirus Infections. Washington: ASM Press; 1995. pp. 193-220. [DOI: 10.1128/9781555818326.ch9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
64 Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol 2003;13:277-91. [DOI: 10.1002/rmv.401] [Cited by in Crossref: 94] [Cited by in F6Publishing: 72] [Article Influence: 5.2] [Reference Citation Analysis]
65 Chaudhry V, Umapathi T, Ravich WJ. Neuromuscular diseases and disorders of the alimentary system. Muscle Nerve 2002;25:768-84. [DOI: 10.1002/mus.10089] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
66 Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev 2017;114:116-31. [PMID: 28438674 DOI: 10.1016/j.addr.2017.04.008] [Cited by in Crossref: 111] [Cited by in F6Publishing: 84] [Article Influence: 27.8] [Reference Citation Analysis]
67 Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines 2015;14:749-62. [PMID: 25597843 DOI: 10.1586/14760584.2015.1001750] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
68 Davitt CJ, Lavelle EC. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev 2015;91:52-69. [PMID: 25817337 DOI: 10.1016/j.addr.2015.03.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 12.8] [Reference Citation Analysis]
69 Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. Vaccines. Elsevier; 2013. pp. 573-97. [DOI: 10.1016/b978-1-4557-0090-5.00034-3] [Cited by in Crossref: 25] [Article Influence: 3.1] [Reference Citation Analysis]
70 Buonagurio DA, Coleman JW, Patibandla SA, Prabhakar BS, Tatem JM. Direct Detection of Sabin Poliovirus Vaccine Strains in Stool Specimens of First-Dose Vaccinees by a Sensitive Reverse Transcription-PCR Method. J Clin Microbiol 1999;37:283-9. [DOI: 10.1128/jcm.37.2.283-289.1999] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
71 Mangal TD, Aylward RB, Grassly NC. The Potential Impact of Routine Immunization with Inactivated Poliovirus Vaccine on Wild-type or Vaccine-derived Poliovirus Outbreaks in a Posteradication Setting. American Journal of Epidemiology 2013;178:1579-87. [DOI: 10.1093/aje/kwt203] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
72 Fiore L, Genovese D, Diamanti E, Catone S, Ridolfi B, Ibrahimi B, konomi R, van der Avoort HGAM, Hovi T, Crainic R, Simeoni P, Amato C. Antigenic and Molecular Characterization of Wild Type 1 Poliovirus Causing Outbreaks of Poliomyelitis in Albania and Neighboring Countries in 1996. J Clin Microbiol 1998;36:1912-8. [DOI: 10.1128/jcm.36.7.1912-1918.1998] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
73 Dowdle WR, Orenstein WA. Quest for life-long protection by vaccination. Proc Natl Acad Sci U S A 1994;91:2464-8. [PMID: 8146140 DOI: 10.1073/pnas.91.7.2464] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
74 Hellen CUT, Wimmer E. Enterovirus Genetics. In: Rotbart HA, editor. Human Enterovirus Infections. Washington: ASM Press; 1995. pp. 25-72. [DOI: 10.1128/9781555818326.ch2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
75 Nathanson N. Eradication of poliovirus: fighting fire with fire. J Infect Dis 2011;203:889-90. [PMID: 21402539 DOI: 10.1093/infdis/jiq148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
76 Plotkin SA. Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis. Rev Med Virol 1997;7:75-81. [DOI: 10.1002/(sici)1099-1654(199707)7:2<75::aid-rmv192>3.0.co;2-o] [Cited by in Crossref: 12] [Article Influence: 0.5] [Reference Citation Analysis]
77 Haastrup E, Thierry-carstensen B, Jensen AM, Stellfeld M, Heilmann C. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells. Vaccine 2004;22:958-62. [DOI: 10.1016/j.vaccine.2003.09.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
78 Macadam AJ, Ferguson G, Stone DM, Meredith J, Knowlson S, Auda G, Almond JW, Minor PD. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 2006;80:8653-63. [PMID: 16912313 DOI: 10.1128/JVI.00370-06] [Cited by in Crossref: 60] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
79 Soto NE, Lutwick LI. Poliovirus immunizations. What goes around, comes around. Infect Dis Clin North Am 1999;13:265-78, ix. [PMID: 10198803 DOI: 10.1016/s0891-5520(05)70054-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS; GeoSentinel Yellow Fever Working Group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001;7:945-51. [PMID: 11747720 DOI: 10.3201/eid0706.010605] [Cited by in Crossref: 102] [Cited by in F6Publishing: 77] [Article Influence: 5.4] [Reference Citation Analysis]
81 Sutter RW, Cochi SL, Patriarca PA. Epidemiologic and laboratory classification systems for paralytic poliomyelitis cases. In: Kurstak E, editor. Measles and Poliomyelitis. Vienna: Springer; 1993. pp. 235-47. [DOI: 10.1007/978-3-7091-9278-8_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, Combiescu AA, Crainic R, Delpeyroux F. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.J Virol. 1997;71:7758-7768. [PMID: 9311861 DOI: 10.1128/JVI.71.10.7758-7768.1997] [Cited by in Crossref: 63] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
83 Prevots DR, Strebel PM. Poliomyelitis Prevention in the United States: New Recommendations for Routine Childhood Vaccination Place Greater Reliance on Inactivated Poliovirus Vaccine. Pediatr Ann 1997;26:378-83. [DOI: 10.3928/0090-4481-19970601-09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
84 Moriniere B, van Loon F, Rhodes P, Patriarca P, Moriniere B, Klein-zabban M, Herrington J, Frank-senat B. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. The Lancet 1993;341:1545-50. [DOI: 10.1016/0140-6736(93)90693-b] [Cited by in Crossref: 56] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
85 Drysdale SB, Barr RS, Rollier CS, Green CA, Pollard AJ, Sande CJ. Priorities for developing respiratory syncytial virus vaccines in different target populations. Sci Transl Med 2020;12:eaax2466. [PMID: 32188721 DOI: 10.1126/scitranslmed.aax2466] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
86 Platt LR, Estivariz CF, Sutter RW. Vaccine-Associated Paralytic Poliomyelitis: A Review of the Epidemiology and Estimation of the Global Burden. Journal of Infectious Diseases 2014;210:S380-9. [DOI: 10.1093/infdis/jiu184] [Cited by in Crossref: 130] [Cited by in F6Publishing: 95] [Article Influence: 18.6] [Reference Citation Analysis]
87 Hull HF, Ward NA, Hull BP, Milstien JB, de Quadros C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet. 1994;343:1331-1337. [PMID: 7910329 DOI: 10.1016/S0140-6736(94)92472-4] [Cited by in Crossref: 130] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
88 Ion-nedelcu N, Dobrescu A, Strebel P, Sutter R. Vaccine-associated paralytic poliomyelitis and HIV infection. The Lancet 1994;343:51-2. [DOI: 10.1016/s0140-6736(94)90903-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
89 Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nat Rev Microbiol 2004;2:473-82. [PMID: 15152203 DOI: 10.1038/nrmicro906] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
90 Shieh YS, Baric RS, Sobsey MD. Detection of low levels of enteric viruses in metropolitan and airplane sewage. Appl Environ Microbiol 1997;63:4401-7. [DOI: 10.1128/aem.63.11.4401-4407.1997] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
91 Finn A, Bell F. Polio vaccine: is it time for a change? Arch Dis Child 1998;78:571-3; discussion 573-4. [PMID: 9713019 DOI: 10.1136/adc.78.6.571] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
92 Jiang B, Patel M, Glass RI. Polio endgame: Lessons for the global rotavirus vaccination program. Vaccine 2019;37:3040-9. [DOI: 10.1016/j.vaccine.2019.04.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Henderson DA. Developed countries should not use inactivated polio vaccine for the prevention of poliomyelitis. Rev Med Virol 1997;7:83-6. [PMID: 10398473 DOI: 10.1002/(sici)1099-1654(199707)7:2<83::aid-rmv193>3.0.co;2-q] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
94 Simasathien S, Migasena S, Beuvery C, Steenis GV, Samakoses R, Pitisuttitham P, Vesikari T. Comparison of Enhanced Potency Inactivated Poliovirus Vaccine (EIPV) Versus Standard Oral Poliovirus Vaccine (OPV) in Thai Infants. Scandinavian Journal of Infectious Diseases 2009;26:731-8. [DOI: 10.3109/00365549409008643] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
95 Patriarca P, Foege W, Swartz T. Progress in polio eradication. The Lancet 1993;342:1461-4. [DOI: 10.1016/0140-6736(93)92936-n] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
96 Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013;33:647-63. [PMID: 22985171 DOI: 10.1111/j.1539-6924.2012.01891.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
97 Yogev R, Edwards KM. Polio vaccination schedules in the United States: The rationale for change. Seminars in Pediatric Infectious Diseases 1999;10:249-57. [DOI: 10.1016/s1045-1870(99)80032-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
98 Chen RT, Mootrey G, DeStefano F. Safety of routine childhood vaccinations. An epidemiological review. Paediatr Drugs 2000;2:273-90. [PMID: 10946416 DOI: 10.2165/00128072-200002040-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
99 Kelly H, Brussen KA, Lawrence A, Elliot E, Pearn J, Thorley B. Polioviruses and other enteroviruses isolated from faecal samples of patients with acute flaccid paralysis in Australia, 1996-2004. J Paediatr Child Health 2006;42:370-6. [DOI: 10.1111/j.1440-1754.2006.00875.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
100 Halsey N. VACCINE SAFETY: REAL AND PERCEIVED ISSUES. The Vaccine Book. Elsevier; 2003. pp. 371-89. [DOI: 10.1016/b978-012107258-2/50028-7] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
101 Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol 1993;67:4630-8. [PMID: 8392604 DOI: 10.1128/JVI.67.8.4630-4638.1993] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
102 Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013;33:680-702. [PMID: 23470192 DOI: 10.1111/risa.12022] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
103 Kelly H. Evidence for a causal association between oral polio vaccine and transverse myelitis: A case history and review of the Literature. J Paediatr Child Health 2006;42:155-9. [DOI: 10.1111/j.1440-1754.2006.00840.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
104 Sutter RW, Maher C. Mass vaccination campaigns for polio eradication: an essential strategy for success. Curr Top Microbiol Immunol 2006;304:195-220. [PMID: 16989271 DOI: 10.1007/3-540-36583-4_11] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
105 Chumakov K, Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008;47:1587-92. [PMID: 18990066 DOI: 10.1086/593310] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
106 Swennen B, Levy J. Oral poliomyelitis vaccine: time to change? Vaccine 2001;19:2262-7. [DOI: 10.1016/s0264-410x(00)00549-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
107 Yang CF, Naguib T, Yang SJ, Nasr E, Jorba J, Ahmed N, Campagnoli R, van der Avoort H, Shimizu H, Yoneyama T, Miyamura T, Pallansch M, Kew O. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 2003;77:8366-77. [PMID: 12857906 DOI: 10.1128/jvi.77.15.8366-8377.2003] [Cited by in Crossref: 159] [Cited by in F6Publishing: 79] [Article Influence: 8.8] [Reference Citation Analysis]
108 Estivariz CF, Molnar Z, Venczel L, Kapusinszky B, Zingeser JA, Lipskaya GY, Kew OM, Berencsi G, Csohan A. Paralytic Poliomyelitis Associated With Sabin Monovalent and Bivalent Oral Polio Vaccines in Hungary. American Journal of Epidemiology 2011;174:316-25. [DOI: 10.1093/aje/kwr070] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
109 de Oliveira LH, Struchiner CJ. Vaccine-associated paralytic poliomyelitis: a retrospective cohort study of acute flaccid paralyses in Brazil. International Journal of Epidemiology 2000;29:757-63. [DOI: 10.1093/ije/29.4.757] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
110 Ravanfar P, Satyaprakash A, Creed R, Mendoza N. Existing antiviral vaccines. Dermatologic Therapy 2009;22:110-28. [DOI: 10.1111/j.1529-8019.2009.01224.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
111 Baicus A. History of polio vaccination. World J Virol 2012;1:108-14. [PMID: 24175215 DOI: 10.5501/wjv.v1.i4.108] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
112 Conrad DA, Jenson HB. New recommendations for poliovirus vaccination: Combination regimen captures best effects of available vaccines. Postgraduate Medicine 2015;102:45-62. [DOI: 10.3810/pgm.1997.11.366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Falman JC, Fagnant-Sperati CS, Kossik AL, Boyle DS, Meschke JS. Evaluation of Secondary Concentration Methods for Poliovirus Detection in Wastewater. Food Environ Virol 2019;11:20-31. [PMID: 30612304 DOI: 10.1007/s12560-018-09364-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
114 Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis 2018;18:165. [PMID: 29631539 DOI: 10.1186/s12879-018-3074-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
115 Begier E, Oberste M, Landry M, Brennan T, Mlynarski D, Mshar P, Frenette K, Rabatsky‐ehr T, Purviance K, Nepaul A, Nix W, Pallansch M, Ferguson D, Cartter M, Hadler J. An Outbreak of Concurrent Echovirus 30 and Coxsackievirus A1 Infections Associated with Sea Swimming among a Group of Travelers to Mexico. CLIN INFECT DIS 2008;47:616-23. [DOI: 10.1086/590562] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
116 Old MO, Logan LH, Maldonado YA. Development of chemiluminescent probe hybridization, RT-PCR and nucleic acid cycle sequencing assays of Sabin type 3 isolates to identify base pair 472 Sabin type 3 mutants associated with vaccine associated paralytic poliomyelitis. Journal of Virological Methods 1997;68:109-18. [DOI: 10.1016/s0166-0934(97)00114-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
117 Paradiso PR. The future of polio immunization in the United States: are we ready for change?: . The Pediatric Infectious Disease Journal 1996;15:645-9. [DOI: 10.1097/00006454-199608000-00002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
118 Mittal SK, Mathew JL. Vaccine Associated Paralytic Poliomyelitis. Indian J Pediatr 2003;70:573-7. [DOI: 10.1007/bf02723161] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
119 Bolanaki E, Kottaridi C, Dedepsidis E, Kyriakopoulou Z, Pliaka V, Pratti A, Levidiotou-Stefanou S, Markoulatos P. Direct extraction and molecular characterization of enteroviruses genomes from human faecal samples. Mol Cell Probes 2008;22:156-61. [PMID: 18378420 DOI: 10.1016/j.mcp.2007.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
120 Dennehy PH. Active immunization in the United States: developments over the past decade. Clin Microbiol Rev 2001;14:872-908, table of contents. [PMID: 11585789 DOI: 10.1128/CMR.14.4.872-908.2001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
121 Halsey NA, Blatter M, Bader G, Thoms ML, Willingham FF, O'donovan JC, Pakula L, Berut F, Reisinger KS, Meschievitz C. Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine: . The Pediatric Infectious Disease Journal 1997;16:675-9. [DOI: 10.1097/00006454-199707000-00010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
122 Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadi G, Tsakogiannis D, Pratti A, Levidiotou-Stefanou S, Markoulatos P. Growth kinetic analysis of bi-recombinant poliovirus vaccine strains. Virus Genes. 2010;40:200-211. [PMID: 20091423 DOI: 10.1007/s11262-010-0448-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
123 Highton AJ, Kojarunchitt T, Girardin A, Hook S, Kemp RA. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunol Cell Biol 2015;93:634-40. [PMID: 25708538 DOI: 10.1038/icb.2015.14] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
124 Kim JS, Hong YJ, Kim JD, Jang YT, Kang JH. Immunogenicity and safety of enhanced-inactivated poliovaccine(eIPV) in healthy Korean infants. Korean J Pediatr 2006;49:864. [DOI: 10.3345/kjp.2006.49.8.864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
125 Cohn AC, Broder KR, Pickering LK. Immunizations in the United States: a rite of passage. Pediatr Clin North Am 2005;52:669-93, v. [PMID: 15925657 DOI: 10.1016/j.pcl.2005.03.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
126 Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. Vaccines. Elsevier; 2008. pp. 631-85. [DOI: 10.1016/b978-1-4160-3611-1.50030-1] [Cited by in Crossref: 24] [Article Influence: 1.8] [Reference Citation Analysis]
127 Ellenberg SS, Foulkes MA, Midthun K, Goldenthal KL. Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health 2005;95:800-7. [PMID: 15855455 DOI: 10.2105/AJPH.2004.039438] [Cited by in Crossref: 38] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
128 Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995;85:1706-9. [PMID: 7503351 DOI: 10.2105/ajph.85.12.1706] [Cited by in Crossref: 114] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
129 Lagos R, Kotloff K, Hoffenbach A, Martin OS, Abrego P, Ureta AM, Pines E, Blondeau C, Bailleux F, Levine MM. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants: . The Pediatric Infectious Disease Journal 1998;17:294-304. [DOI: 10.1097/00006454-199804000-00006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
130 D'Amelio E, Salemi S, D'Amelio R. Anti-Infectious Human Vaccination in Historical Perspective. Int Rev Immunol 2016;35:260-90. [PMID: 26606466 DOI: 10.3109/08830185.2015.1082177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
131 Collett MS, Neyts J, Modlin JF. A case for developing antiviral drugs against polio. Antiviral Research 2008;79:179-87. [DOI: 10.1016/j.antiviral.2008.04.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
132 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
133 Kaslow RA, Evans AS. Epidemiologic Concepts and Methods. In: Evans AS, Kaslow RA, editors. Viral Infections of Humans. Boston: Springer US; 1997. pp. 3-58. [DOI: 10.1007/978-1-4899-0036-4_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Kapusinszky B, Molnár Z, Szomor KN, Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol 2010;58:211-7. [DOI: 10.1111/j.1574-695x.2009.00621.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
135 Paximadi E, Karakasiliotis I, Mamuris Z, Stathopoulos C, Krikelis V, Markoulatos P. Genomic analysis of recombinant sabin clinical isolates. Virus Genes 2006;32:203-10. [PMID: 16604453 DOI: 10.1007/s11262-005-6877-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
136 Landaverde JM, Trumbo SP, Danovaro-holliday MC, Cochi SE, Gandhi R, Ruiz-matus C. Vaccine-Associated Paralytic Poliomyelitis in the Postelimination Era in Latin America and the Caribbean, 1992–2011. The Journal of Infectious Diseases 2014;209:1393-402. [DOI: 10.1093/infdis/jit602] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
137 Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011;239:125-48. [PMID: 21198669 DOI: 10.1111/j.1600-065X.2010.00970.x] [Cited by in Crossref: 165] [Cited by in F6Publishing: 76] [Article Influence: 16.5] [Reference Citation Analysis]
138 Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, Yuen L, Utama A, Tano Y, Arita M, Yoshida H, Yoneyama T, Benegas A, Roesel S, Pallansch M, Kew O, Miyamura T. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 2004;78:13512-21. [PMID: 15564462 DOI: 10.1128/JVI.78.24.13512-13521.2004] [Cited by in Crossref: 107] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
139 Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. Vaccines. Elsevier; 2013. pp. 598-645. [DOI: 10.1016/b978-1-4557-0090-5.00035-5] [Cited by in Crossref: 36] [Article Influence: 4.5] [Reference Citation Analysis]